Carlyn Tan, MD, Memorial Sloan Kettering Cancer Center, New York City, NY, briefly discusses the ongoing research on bispecific antibodies for multiple myeloma, focusing on alternative antigen targets beyond BCMA. Dr Tan comments on two promising drugs: cevostamab which targets FcRH5, and talquetamab, which targets GPRC5D. This interview took place at the 28th Congress of the European Hematology Association (EHA) 2023 in Frankfurt, Germany.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

свернуть